Estado del arte en primera línea de CPNM en pacientes sin mutaciones Driver Monoterapia vs combinación

Previous Page

Next Page

Page Background

CheckMate 227: Nivo + Ipi in 1L NSCLC With High TMB (≥10 mut/Mb)

PFS: Nivolumab + Chemotherapy and Nivolumab + Ipilimumab <br />By TMB

Presented By Hossein Borghaei at 2018 ASCO Annual Meeting